Cargando…

Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate

The N,C-coupled naphthylisoquinoline alkaloid ancistrocladinium A belongs to a novel class of natural products with potent antiprotozoal activity. Its effects on tumor cells, however, have not yet been explored. We demonstrate the antitumor activity of ancistrocladinium A in multiple myeloma (MM), a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brünnert, Daniela, Seupel, Raina, Goyal, Pankaj, Bach, Matthias, Schraud, Heike, Kirner, Stefanie, Köster, Eva, Feineis, Doris, Bargou, Ralf C., Schlosser, Andreas, Bringmann, Gerhard, Chatterjee, Manik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459547/ https://www.ncbi.nlm.nih.gov/pubmed/37631095 http://dx.doi.org/10.3390/ph16081181

Ejemplares similares

Efficient Transient Transfection of Human Multiple Myeloma Cells by Electroporation – An Appraisal
por: Steinbrunn, Torsten, et al.
Publicado: (2014)

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS
por: Seibold, Marcel, et al.
Publicado: (2019)

Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma
por: Leich, Ellen, et al.
Publicado: (2021)

Targeting of the E3 ubiquitin-protein ligase HUWE1 impairs DNA repair capacity and tumor growth in preclinical multiple myeloma models
por: Kunz, Viktoria, et al.
Publicado: (2020)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Jayaweera, Shansa Pranami E., et al.
Publicado: (2021)

Antiplasmodial Ealapasamines A-C,‘Mixed’ Naphthylisoquinoline Dimers from the Central African Liana Ancistrocladus ealaensis
por: Tshitenge, Dieudonné Tshitenge, et al.
Publicado: (2017)

Michellamines A(6) and A(7), and further mono- and dimeric naphthylisoquinoline alkaloids from a Congolese Ancistrocladus liana and their antiausterity activities against pancreatic cancer cells
por: Lombe, Blaise Kimbadi, et al.
Publicado: (2018)

Antiprotozoal dimeric naphthylisoquinolines, mbandakamines B(3) and B(4), and related 5,8′-coupled monomeric alkaloids, ikelacongolines A–D, from a Congolese Ancistrocladus liana
por: Mufusama, Jean-Pierre, et al.
Publicado: (2019)

Ancistrobreveines A–D and related dehydrogenated naphthylisoquinoline alkaloids with antiproliferative activities against leukemia cells, from the West African liana Ancistrocladus abbreviatus
por: Fayez, Shaimaa, et al.
Publicado: (2019)

An Unusually Broad Series of Seven Cyclombandakamines, Bridged Dimeric Naphthylisoquinoline Alkaloids from the Congolese Liana Ancistrocladus ealaensis
por: Tshitenge, Dieudonné Tshitenge, et al.
Publicado: (2019)

Naphthylisoindolinone alkaloids: the first ring-contracted naphthylisoquinolines, from the tropical liana Ancistrocladus abbreviatus, with cytotoxic activity
por: Fayez, Shaimaa, et al.
Publicado: (2022)

Correction: Naphthylisoindolinone alkaloids: the first ring-contracted naphthylisoquinolines, from the tropical liana Ancistrocladus abbreviatus, with cytotoxic activity
por: Fayez, Shaimaa, et al.
Publicado: (2022)

AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2022)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Correction: AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2023)

Cofilin Oligomer Formation Occurs In Vivo and Is Regulated by Cofilin Phosphorylation
por: Goyal, Pankaj, et al.
Publicado: (2013)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)

Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2010)

Quantitative Phosphoproteomics of Proteasome Inhibition in Multiple Myeloma Cells
por: Ge, Feng, et al.
Publicado: (2010)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
por: Merin, Noah M., et al.
Publicado: (2014)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Proteasome inhibition: the dawn of novel therapies in multiple myeloma
por: Engelhardt, Monika, et al.
Publicado: (2022)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
por: Boulos, Joelle C., et al.
Publicado: (2021)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

Identification of gefitinib off-targets using a structure-based systems biology approach; their validation with reverse docking and retrospective data mining
por: Verma, Nidhi, et al.
Publicado: (2016)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

Novel strategies to target the ubiquitin proteasome system in multiple myeloma
por: Lub, Susanne, et al.
Publicado: (2015)

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
por: Park, Jonghoon, et al.
Publicado: (2016)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
por: Paradzik, Tina, et al.
Publicado: (2021)

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms
por: Rauert, H, et al.
Publicado: (2011)

Multiple Myeloma Presenting as Thyroid Plasmacytoma
por: Singh, Kaalindi, et al.
Publicado: (2017)

In Silico, In Vitro, and In Vivo Investigations on Adapalene as Repurposed Third Generation Retinoid against Multiple Myeloma and Leukemia
por: Boulos, Joelle C., et al.
Publicado: (2023)

Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma
por: Keppler, Sarah, et al.
Publicado: (2016)

Immunotherapy of Multiple Myeloma: Promise and Challenges
por: Abramson, Hanley N
Publicado: (2021)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors
por: Mendonca, Nikolai P., et al.
Publicado: (2016)

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
por: Qiang, Ya-Wei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hcbdl7uqr80elhadpaoqtr8p3p